Targeting myeloid cells and modulation of their function by fully synthetic antibody mimetics

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F23%3A00618341" target="_blank" >RIV/61388963:_____/23:00618341 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Targeting myeloid cells and modulation of their function by fully synthetic antibody mimetics

Popis výsledku v původním jazyce

This study explores the selective targeting of CD64-expressing cells using iBodies, synthetic antibody mimetics conjugated to HPMA polymers. The conjugation significantly improves the binding affinity of Ligand L1, enhancing the specificity and efficacy of iBodies. Anti-CD64 iBodies demonstrated high specificity for monocytes and macrophages, confirmed through flow cytometry and confocal microscopy. Furthermore, cytotoxic iBodies selectively eliminated M2 macrophages while sparing M1 macrophages. These findings suggest that iBodies have strong potential for use in cancer immunotherapy by modulating immune responses and targeting tumor-associated macrophages.

Název v anglickém jazyce

Targeting myeloid cells and modulation of their function by fully synthetic antibody mimetics

Popis výsledku anglicky

This study explores the selective targeting of CD64-expressing cells using iBodies, synthetic antibody mimetics conjugated to HPMA polymers. The conjugation significantly improves the binding affinity of Ligand L1, enhancing the specificity and efficacy of iBodies. Anti-CD64 iBodies demonstrated high specificity for monocytes and macrophages, confirmed through flow cytometry and confocal microscopy. Furthermore, cytotoxic iBodies selectively eliminated M2 macrophages while sparing M1 macrophages. These findings suggest that iBodies have strong potential for use in cancer immunotherapy by modulating immune responses and targeting tumor-associated macrophages.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30102 - Immunology

Projekt

<a href="/cs/project/LX22NPO5102" target="_blank" >LX22NPO5102: Národní ústav pro výzkum rakoviny</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů